Friday, 19 Jan 2018

You are here

NSAID and Opioid Adverse Event Reports from MedWatch

One-third of adults in the USA experience chronic pain and take prescription nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or opioids. This report from the MedWatch system shows that 20% of reports were associated with death, with near equal contribution by NSAIDs, opioids and combination (NSAIDs plus opioids).

With growing concern over the safety of these agents, investigators reviewed data collected between 2015 and 2016 from the FDA’s Adverse Events Reporting System (FAERS or MedWatch) to analyze the comparative frequencies and demographics of those reporting painkiller-related AEs.

Over 2 million adverse event (AE) reports were submitted to FAERS during this period and nearly 3% (64,354) were were associated with painkillers.

Opioid-associated AEs were more likely to be from males or younger patients (mean age 47.6 years). The

The most frequent AEs were from drug ineffectiveness, administration issues, abuse, and overdose associated with NSAID and opioid use.

Death was reported in 20.0% of the reports, and serious adverse reactions (SAE), including death, were reported in two-thirds.

Death and SAEs highest among patients using opioids or combinations users.

Given the great focus on opioid hazards, these data suggest that NSAIDs and combination painkillers may be as hazardous as opioids when looking at FAERS reports.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Prevention of HBV Infection: How Are We Doing?

In 2016 the WHO set out to eliminate HBV infection as a public health threat by 2030. So far, we are far from this goal as vaccine implementation has been suboptimal in a number of important patient populations, including patients with rheumatologic diseases, as well as other immunocompromising diseases like HIV.

B Cell Changes Predict Autoimmunity with Checkpoint Inhibitors

The Journal of Clinical Investigation reports results of a study showing that increases in CD21lo B cells and plasmablasts following that combination checkpoint blockade preceded the onset of immune-related adverse events.

While some have postulated that IRAEs are thought to be T cell mediated, B cells have also been implicated. Investigators studied 39 melanoma patients undergoing treatment with either anti-CTLA4 or anti-PD1, or combination CCB therapy. They analyzed changes in circulating B cells before and after the first cycle of therapy of immune checkpoint blockade (23 received combination therapy, 8 received anti-CTLA4, and 8 received anti-PD1).

Ibuprofen’s Anti-androgenic Effect May Result in Hypogonadism in Males

PNAS reports use of ibuprofen by males may result in antiandrogen effects that may contribute to adult male reproductive problems.

Sorting Out the Complexities of Autoimmunity with Immune Checkpoint Inhibitor Therapy

An editorial and systematic review of complications seen when checkpoint inhibitor (CPI) therapies are given to patients with immune mediated inflammatory disorders (IMIDs) and cancer shows that nearly 75% manifest autoimmune and inflammatory immune-related adverse events (irAEs).

Baseline Risk Score Predicts Serious Infection Risk in TNF-Treated RA Patients

Curtis and colleagues have analyzed the certolizumab (CZP) RAPID1 and RAPID2 trials to assess the risk of serious infectious events (SIEs), and shown that steroids combined with an age-adjusted comorbidity index (AACI) yields a 2-3 fold predictable risk for SIE.